ILX Stock Overview
Ilex Medical Ltd engages in marketing, selling, and supporting equipment, disposables, and reagents for laboratories and healthcare establishments in Israel and South Africa.
Ilex Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₪121.70|
|52 Week High||₪170.70|
|52 Week Low||₪98.60|
|1 Month Change||-3.64%|
|3 Month Change||-16.13%|
|1 Year Change||14.70%|
|3 Year Change||84.31%|
|5 Year Change||181.32%|
|Change since IPO||3,728.38%|
Recent News & Updates
Ilex Medical (TLV:ILX) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
The Trend Of High Returns At Ilex Medical (TLV:ILX) Has Us Very Interested
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
|ILX||IL Healthcare||IL Market|
Return vs Industry: ILX exceeded the IL Healthcare industry which returned -27.5% over the past year.
Return vs Market: ILX exceeded the IL Market which returned 7.1% over the past year.
|ILX Average Weekly Movement||5.4%|
|Healthcare Industry Average Movement||5.4%|
|Market Average Movement||5.6%|
|10% most volatile stocks in IL Market||8.8%|
|10% least volatile stocks in IL Market||3.7%|
Stable Share Price: ILX is not significantly more volatile than the rest of IL stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ILX's weekly volatility (5%) has been stable over the past year.
About the Company
Ilex Medical Ltd engages in marketing, selling, and supporting equipment, disposables, and reagents for laboratories and healthcare establishments in Israel and South Africa. The company offers in vitro diagnostic equipment and reagent systems to hospitals, clinics, and other medical institutions; molecular biology products for cancer screening, retro virus viral load, TB, STDs, and other infectious diseases; and equipment, disposables, and reagents for in vitro fertilization, as well as food and pharma industries. It also distributes and supports nucleic acid testing blood screening solutions to large-scale blood banks; provides pre/post analytics and robotics; and develops, markets, implements, and supports laboratory information systems.
Ilex Medical Fundamentals Summary
|ILX fundamental statistics|
Is ILX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ILX income statement (TTM)|
|Cost of Revenue||₪632.05m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||17.97|
|Net Profit Margin||19.66%|
How did ILX perform over the long term?See historical performance and comparison
4.4%Current Dividend Yield
Is ILX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ILX?
Other financial metrics that can be useful for relative valuation.
|What is ILX's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does ILX's PE Ratio compare to its peers?
|ILX PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: ILX is good value based on its Price-To-Earnings Ratio (6.8x) compared to the peer average (16.1x).
Price to Earnings Ratio vs Industry
How does ILX's PE Ratio compare vs other companies in the Healthcare Industry?
Price-To-Earnings vs Industry: ILX is good value based on its Price-To-Earnings Ratio (6.8x) compared to the Asian Healthcare industry average (17.1x)
Price to Earnings Ratio vs Fair Ratio
What is ILX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||6.8x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ILX's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ILX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ILX (₪121.7) is trading below our estimate of fair value (₪419.24)
Significantly Below Fair Value: ILX is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ILX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Ilex Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ilex Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Ilex Medical is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
How has Ilex Medical performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ILX has high quality earnings.
Growing Profit Margin: ILX's current net profit margins (19.7%) are higher than last year (13.8%).
Past Earnings Growth Analysis
Earnings Trend: ILX's earnings have grown significantly by 40.6% per year over the past 5 years.
Accelerating Growth: ILX's earnings growth over the past year (39.1%) is below its 5-year average (40.6% per year).
Earnings vs Industry: ILX earnings growth over the past year (39.1%) exceeded the Healthcare industry 31.2%.
Return on Equity
High ROE: ILX's Return on Equity (35.9%) is considered high.
Discover strong past performing companies
How is Ilex Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ILX's short term assets (₪630.1M) exceed its short term liabilities (₪287.1M).
Long Term Liabilities: ILX's short term assets (₪630.1M) exceed its long term liabilities (₪56.2M).
Debt to Equity History and Analysis
Debt Level: ILX has more cash than its total debt.
Reducing Debt: ILX's debt to equity ratio has reduced from 37% to 0.4% over the past 5 years.
Debt Coverage: ILX's debt is well covered by operating cash flow (10755.2%).
Interest Coverage: ILX's interest payments on its debt are well covered by EBIT (189.3x coverage).
Discover healthy companies
What is Ilex Medical current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ILX's dividend (4.37%) is higher than the bottom 25% of dividend payers in the IL market (2.06%).
High Dividend: ILX's dividend (4.37%) is low compared to the top 25% of dividend payers in the IL market (6.24%).
Stability and Growth of Payments
Stable Dividend: ILX's dividend payments have been volatile in the past 10 years.
Growing Dividend: ILX's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (29.6%), ILX's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (31.2%), ILX's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tammy Galili (49 yo)
Mrs. Tammy Galili has been the Chief Executive Officer of Ilex Medical Ltd since February 14, 2016 and served as its Executive Vice President. She is Director at Kadimastem Ltd since 2022. Mrs. Galili serv...
CEO Compensation Analysis
Compensation vs Market: Tammy's total compensation ($USD560.49K) is about average for companies of similar size in the IL market ($USD719.35K).
Compensation vs Earnings: Tammy's compensation has been consistent with company performance over the past year.
Experienced Management: ILX's management team is considered experienced (4.4 years average tenure).
Experienced Board: ILX's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ilex Medical Ltd's employee growth, exchange listings and data sources
- Name: Ilex Medical Ltd
- Ticker: ILX
- Exchange: TASE
- Founded: 1977
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: ₪1.373b
- Shares outstanding: 11.28m
- Website: https://www.ilexmedical.com
Number of Employees
- Ilex Medical Ltd
- Kodak Building
- 7 Hatnufa Street
- Petah Tikva
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/25 00:00|
|End of Day Share Price||2022/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.